BUFFALO, N.Y. — A nationwide clinical research study is underway that aims to validate that a blood test can be an easy and accurate option to detect colorectal cancer.
The Colorectal Cancer Alliance (CCA) is partnering with Freenome, a South San Francisco-based biotech company, to recruit people for the study.
They’re looking for 14,000 participants in the United States.
The study is open to people ages 45 to 85 who are of average risk and who plan to undergo a routine colonoscopy. The blood test is paired with that traditional screening. There’s no medication or treatment required.
Freenome plans to submit the findings to the FDA for approval, a process that could take several years.